San Diego, CA | Nov 5 2018
Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in SynapCell's Genetic Absence Epilepsy Model (GAERS) Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases,
San Diego, CA | Oct 29 2018
Absence epilepsy is a form of epileptic syndrome where patients show generalized non-convulsive seizures characterized by a brief unresponsiveness to environmental stimuli and cessation of activity. In human, typical absence seizures are associated with bilateral, synchronous and regular
Brain-focused CRO, we support your Drug Discovery programs in Epilepsy, Parkinson, Alzheimer, Schizophrenia and Essential Tremor with predictive and translational Pharmacodynamic assays in vivo at the Preclinical stage.
Saint Ismier, France | MARCH 21 2018
Baptisée NeurOsyn-alliance, cette solution unique et innovante, fruit d’une étroite collaboration entre les deux sociétés françaises, permet de simplifier le parcours de sélection de candidats médicaments pour les industriels. Il s’agit d’une approche combinée 2D 3D basée sur
Saint Ismier, France | MARCH 19 2018
Installée dans de nouveaux locaux où sont réunies toutes ses activités, la société SynapCell, spécialisée dans l’expertise préclinique de médicaments pour les pathologies du cerveau, accélère sa croissance. “Notre pari il y a trois ans de cibler d’autres pathologies que
Grenoble, France | FEB 12 2018
Today is the International Epilepsy Day. #EPILEPSYDAY An epileptic disorder is a chronic neurological condition characterized by recurrent epileptic seizures. Epileptic seizures are characterized by a hypersynchrony and hyperexcitability of one, or several, neural networks, leading to the
Washington, D.C | Nov 15 2017
Neuroservice and SynapCell are very pleased to announce the launch of a joint product, neurOsyn. This new offer combines a unique in vitro and in vivo approach to document your compound’s effects on brain oscillations. Neuroservice has developed over the last 3 years in vitro Multi-Electrode
Miami, USA | June 2017
Just back from Miami, USA where I had the chance to attend The Anti Epileptic Drug and Devices Trials Conference two weeks ago. We have been very proud to see that SynapCell now belongs to the restricted veteran club of this meeting, as it’s indeed been already 8 years since we’ve started
Grenoble and Salt Lake City | 03/11/2016
SYNAPCELL RE-ESTABLISHES PARTNERSHIP WITH THE UNIVERSITY OF UTAH TO SCREEN NOVEL ANTI-EPILEPTIC MEDICATIONS The University of Utah has awarded a subcontract to SynapCell as part of the NIH/NINDS Epilepsy Therapy Screening Program (ETSP). The partnership between SynapCell and the University of
Grenoble | February 26 2016
We are delighted to share with you the publication of our article about the MTLE mouse: a model of focal epilepsy in CNS Neuroscience and Therapeutics. Our work is entitled "Differential effects of antiepileptic drugs on focal seizures in the intrahippocampal kainate mouse model of Mesial Temporal
France | 2nd December 2014
Synapcell to assess the potential of UCB's candidate molecules in the field of epilepsy. The two-year agreement will take advantage of SynapCell’s MTLE (mesial temporal lobe epilepsy) mouse solutions. More than 65 million people world-wide are affected by epilepsy (WHO). Full drug development
Grenoble | APRIL 24TH, 2014
The recent clinical data obtained with a new antiepileptic drug (AED) candidate called pitolisant, developed by Bioprojet, in an early Phase II study confirms the interest in SynapCell's strategic approach, associating animal models and EEG, as a translational marker of brain's function. Moreover,
Salt Lake City | January 29th, 2014
The University of Utah awards a subcontract to SynapCell to expand anti-seizure drug screening and testing capabilities in animal models of therapy-resistant epilepsy. The University of Utah has awarded a one-year subcontract to SynapCell under the Anticonvulsant Screening Program (ASP)